Supporting Information S1

Novel KCNQ2/Q3 Agonists as Potential Therapeutics for Epilepsy and Neuropathic Pain

Paul C. Fritch, Grant McNaughton-Smith, George S. Amato, James F. Burns, C. Wesley Eargle, Rosemarie Roeloffs, William Harrison, Leslie Jones, and Alan D. Wickenden.*

Icagen, Inc., Suite 390, 4222 Emperor Blvd., Durham, NC, 27703, USA

Cerep receptor panel binding assay for compounds 6e, 6f, and 6o

Cerep Receptor Panel Binding Assay (% Displacement of Ligand)

Conc uM	Assay	6e	6f	6o
10	Adenosine A1	0	0	11
10	Adenosine A2A	0	12	10
10	Alpha-1 Nonselective	0	0	11
10	Alpha-2 nonselective	0	0	0
10	Beta-1 Adrenergic	0	0	11
10	Norephrine Uptake	14	34	43
10	Angiotensin-I	0	18	14
10	Benzodiazepine Central	0	0	22
10	Bradykinin B2	0	49	0
10	Cholecystokinin A	0	53	11
10	Dopamine D1	0	0	0
10	Dopamine D2	0	0	0
10	Dopamine Uptake	0	21	0
10	Endothelin A	0	0	0
10	Gaba Nonselective	16	12	0
10	N-Methyl-D-Aspartate	0	0	0
10	Histamine H1	22	0	0
10	Muscarinic Nonselective	0	34	21
10	Neurokinin 1	0	21	10
10	Neuropeptide Y Nonselective	0	33	0
10	Nicotinic Neuronal BGTX-Inses	0	16	11
10	Opiate Nonselective	0	0	13
10	Phencyclidine PCP	0	0	0

10	Serotonin Nonselective	0	20	14
10	Serotonin 5HT1B	0	0	0
10	Serotonin 5HT2A	0	0	18
10	Serotonin Uptake	20	50	16
10	Sigma Nonselective	0	0	19
10	Glucocorticoid	0	14	0
10	Vassopressin V1	12	22	0
10	Cannabinoid-1			19
10	Cannabinoid-2			0
10	Delta Opiate			10
10	Kappa Opiate			15
30	Kappa Opiate			0
10	Mu Opiate			0
10	Calcium Channel DHP Site			0
10	Calcium Channel Diltiazem Site			0
10	Calcium Channel Verapamil Site			0
10	Calcium Channel N-Type			0
10	Sodium Channel Site Two			35